Literature DB >> 12411982

Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure.

Reginald F Frye1, Virginia M Schneider, Carole S Frye, Arthur M Feldman.   

Abstract

BACKGROUND: Cytochrome P450 (CYP) enzymes are important mediators of drug metabolism, and activity of these enzymes is a major determinant of the duration and intensity of drug effect. Circulating plasma concentrations of pro-inflammatory cytokines (e.g., tumor necrosis factor [TNF]-alpha and interleukin [IL]-6) are elevated in patients with heart failure and these cytokines have been shown to down-regulate CYP enzyme activity. The purpose of this study was to evaluate the relationship between plasma cytokine concentrations and CYP enzyme activities in patients with heart failure. METHODS AND
RESULTS: Sixteen patients with congestive heart failure (New York Heart Association classes II-IV) received a metabolic probe cocktail consisting of caffeine, mephenytoin, dextromethorphan, and chlorzoxazone to assess the activities of the CYP enzymes 1A2, 2C19, 2D6, and 2E1. Blood and urine samples were collected for drug and metabolite determinations by high-performance liquid chromatography (HPLC); cytokine concentrations were measured by enzyme-linked immunosorbent assay (ELISA). We found a striking inverse relationship between both TNF-alpha and IL-6 plasma concentrations and the activity of CYP2C19; metabolism of caffeine (CYP1A2) also had a negative association with IL-6 plasma concentrations.
CONCLUSIONS: Cytokine-mediated decreases in drug metabolism may contribute to observed variability in drug response and augment the risk of adverse drug effects in CHF patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411982     DOI: 10.1054/jcaf.2002.127773

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  40 in total

1.  Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction.

Authors:  M C Cornelis; A El-Sohemy; H Campos
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

2.  DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes.

Authors:  Mao Zhao; Luan Xiaofei; Cao Gang; Liu Wei; Xiong Jing; Hu Gang; Chen Ruini; Ning Rui; Shang Wei; Yang Jian; Yan Bingfang
Journal:  Biochem Pharmacol       Date:  2012-06-21       Impact factor: 5.858

Review 3.  Vaccine-Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms.

Authors:  Paolo Pellegrino; Cristiana Perrotta; Emilio Clementi; Sonia Radice
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

4.  Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.

Authors:  Sebastian Trousil; Patrizia Lee; Robert J Edwards; Lynn Maslen; Jingky P Lozan-Kuehne; Ramya Ramaswami; Eric O Aboagye; Stephen Clarke; Christopher Liddle; Rohini Sharma
Journal:  Br J Pharmacol       Date:  2019-08-05       Impact factor: 8.739

5.  Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop.

Authors:  Jane R Kenny; Maggie M Liu; Andrew T Chow; Justin C Earp; Raymond Evers; J Greg Slatter; Diane D Wang; Lei Zhang; Honghui Zhou
Journal:  AAPS J       Date:  2013-06-21       Impact factor: 4.009

6.  Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.

Authors:  Charles S Venuto; Jihoon Lim; Susan Messing; Peter W Hunt; Grace A McComsey; Gene D Morse
Journal:  Antivir Ther       Date:  2018

7.  ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies.

Authors:  Rashmi R Shah; Joel Morganroth; Robert B Kleiman
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 8.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

Review 9.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

10.  Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

Authors:  Alison E Aitken; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2007-06-18       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.